BEPREVE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BEPREVE (BEPREVE).
Bepotastine besilate is a selective histamine H1 receptor antagonist. It inhibits histamine-induced vascular permeability, pruritus, and conjunctival inflammation.
| Metabolism | Minimally metabolized; 80% excreted unchanged in urine. |
| Excretion | Bepotastine besilate is primarily excreted via renal elimination. Approximately 75-80% of the administered dose is eliminated unchanged in the urine, with less than 10% recovered in feces. Minor biliary excretion occurs. |
| Half-life | Plasma elimination half-life is approximately 2-3 hours in healthy adults. In patients with renal impairment, half-life may be prolonged (up to 6-8 hours in severe impairment). |
| Protein binding | Approximately 55% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.8 L/kg, indicating distribution into total body water. This suggests moderate tissue penetration. |
| Bioavailability | Ophthalmic: Systemic bioavailability is low (less than 1%) due to local administration and limited absorption. No oral bioavailability data as the drug is not administered systemically. |
| Onset of Action | Ophthalmic administration: Onset of ocular itch relief within 3 minutes post-instillation; maximal effect at 15 minutes. |
| Duration of Action | Duration of action for ocular itch prevention is up to 8 hours after a single dose, supporting twice-daily dosing. Clinical efficacy maintained with regular use. |
| Molecular Weight | 280.35 |
1 drop in the affected eye(s) twice daily (approximately every 6-8 hours).
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients below 2 years of age have not been established. For pediatric patients 2 years and older, same as adult dose: 1 drop twice daily. |
| Geriatric use | No specific dose adjustment required; dosing same as for younger adults. |
| 1st trimester | Avoid use; no adequate studies in pregnant women. Animal studies have shown embryotoxicity at high doses. |
| 2nd trimester | Use only if potential benefit justifies potential risk to fetus; limited human data. |
| 3rd trimester | Use only if necessary; may cause neonatal apnea if administered near term. |
Clinical note
Comprehensive clinical and safety monograph for BEPREVE (BEPREVE).
| Placental transfer | Probable; crosses placenta in animal studies. |
| Breastfeeding | Not recommended during breastfeeding due to potential for serious adverse reactions in nursing infants; consider discontinuing drug or nursing. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to bepotastine or any excipient
| Precautions | Not for injection; for topical ophthalmic use only., Avoid wearing contact lenses if eyes are red., May cause transient stinging or burning upon instillation. |
| Food/Dietary | No known food interactions. |
| Clinical Pearls | Bepotastine besilate (Bepreve) is a topical antihistamine and mast cell stabilizer for ocular allergy. Onset of action is within 3 minutes, duration up to 8 hours. May cause transient stinging. Do not use while wearing contact lenses; insert lenses 10 minutes after instillation. |
Loading safety data…
| L4 - Possibly Hazardous |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal studies revealed no evidence of teratogenicity or fetotoxicity at doses up to 2000 times the human ocular dose. Risk cannot be ruled out; use only if potential benefit justifies potential risk to the fetus. |
| Fetal Monitoring | No specific monitoring required beyond standard prenatal care. Observe for any adverse ocular effects if used during pregnancy. |
| Fertility Effects | No studies on fertility in humans. Animal studies showed no impairment of fertility at doses up to 2000 times the human ocular dose. |
| Patient Advice | Instill one drop into the affected eye(s) twice daily. · Remove contact lenses before use; wait at least 10 minutes before reinserting. · Do not touch the dropper tip to any surface to avoid contamination. · May cause temporary blurred vision; avoid driving until vision clears. · Report any signs of infection or worsening symptoms to your doctor. |